ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
A prospective Phase II clinical study to assess the efficacy and toxicity of high dose
chemotherapy (HDT) followed by allogeneic stem cell transplantation (allo- or autoSCT) as
treatment of primary progressive and relapsed aggressive Non-Hodgkin Lymphoma (NHL) - ASTRAL